Zepbound

Zepbound’s (tirzepatide) relationship to Alzheimer’s risk involves complex metabolic pathways — insulin resistance, inflammation, and neuroprotective

Zepbound isn’t FDA-approved for smoking cessation, but emerging research shows GLP-1 receptor agonists may reduce nicotine cravings through dopamine

Zepbound (tirzepatide) shows emerging evidence for reducing alcohol cravings through GLP-1 receptor pathways—here’s what patients need to know.

Zepbound doesn’t cause gambling addiction, but dual GIP/GLP-1 agonism affects dopamine pathways—here’s what patients taking tirzepatide need to know.

Zepbound doesn’t cause compulsive shopping — but sudden appetite suppression can shift reward-seeking behavior toward other dopamine triggers, including

Semaglutide telehealth Alabama connects patients with licensed providers remotely — consultations, prescriptions, and home delivery without office visits.

Zepbound treats obesity but isn’t FDA-approved for social anxiety. Learn why some patients report mood changes and what the evidence shows about GLP-1s

Zepbound isn’t approved for Cushing’s syndrome, but weight management remains critical. Learn safety considerations, contraindications, and alternatives.

Zepbound requires a two-month washout before conception. We explain why stopping early matters, what research shows, and when it’s safe to try.